Bachem Holding AG (LON:0QND)

Market Cap	4.91B +21.5%
Revenue (ttm)	651.29M +14.8%
Net Income	139.42M +23.7%
EPS	1.86 +23.8%
Shares Out	n/a
PE Ratio	35.25
Forward PE	29.22
Dividend	0.85 (1.24%)
Ex-Dividend Date	May 4, 2026

Volume	804
Open	69.95
Previous Close	70.35
Day's Range	69.50 - 71.30
52-Week Range	48.70 - 83.25
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1971
• Employees: 2,363
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QND

Financial Performance

In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.

Financial numbers in CHF

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 20, 2026

Data Sources Report a data error